Brought to you by 
EUSA Pharma Inc.
http://www.eusapharma.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From EUSA Pharma Inc.
Merck & Pfizer Win English Funding For Kidney Cancer Combo
NICE says that Bavencio plus Inlyta will be made available via the Cancer Drugs Fund for advanced kidney cancer while more evidence is collected to support the combination therapy's routine use on the National Health Service.
Austria’s Apeiron To Attack COVID-19 At Its Entry Point
Apeiron Biologics has fashioned a recombinant version of the enzyme to which SARS-CoV-2 is thought to bind, and with governmental help has started a Phase II study in Austria, Germany and Denmark.
Finance Watch: VCs Are Sharing The Wealth With More Biopharmas
Private Company Edition: While venture capital invested in the industry dropped in 2019, the number of deals rose as investors funded more early-stage VC rounds. Money continues flowing to large deals as well, including $105m for ALX Oncology and $98m for CANbridge.
Asia Deal Watch: BeiGene Gets Chinese Rights To Two EUSA Rare Disease Therapies
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Medical Devices
- Implantable Devices
- Other Names / Subsidiaries
-
- Cytogen Corporation